Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race

Hepatology

Volumn 44, Issue 2, 2006, Pages 352-359

  He, Xiao Song ^a,b   Ji, Xuhuai ^a,b   Hale, Matthew B ^a   Cheung, Ramsey ^a,b   Ahmed, Aijaz ^a   Guo, Yaqian ^c   Nolan, Garry P ^a   Pfeffer, Lawrence M ^d   Wright, Teresa L ^e   Risch, Neil ^f,g   Tibshirani, Robert ^c   Greenberg, Harry B ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; JANUS KINASE; PEGINTERFERON; RIBAVIRIN; STAT1 PROTEIN;

ADULT; ARTICLE; CAUCASIAN; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ACTIVITY; ETHNIC GROUP; GENETIC TRANSCRIPTION; HEPATITIS C; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NEGRO; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS GENE;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIVIRAL AGENTS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; TRANS-ACTIVATION (GENETICS); UNITED STATES;

EID: 33747059871     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21267     Document Type: Article

References (26)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
2. Fried MW, Shiftman ML, Reddy KR, Smith C, Marines G, Goncales FL Jr, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
3. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. HEPATOLOGY 1999;30:787-793.
4. Kinzie JL, Naylor PH, Nathani MG, Peleman RR, Ehrinpreis MN, Lybik M, et al. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepat 2001;8:264-269.
5. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. HEPATOLOGY 2003;37:1343-1350.
6. Theodore D, Shiffman ML, Sterling RK, Bruno CJ, Weinstein J, Crippin JS, et al. Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis C. Dig Dis Sci 2003;48:140-145.
7. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alpha-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350:2265-2271.
8. Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004;117:163-168.
9. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998;67:227-264.
10. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001;14:778-809.
11. Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005;128:1437-1444.
12. Lempicki RA, Polis MA, Yang J, McLaughlin M, Koratich C, Huang DW, et al. Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons. J Infect Dis 2006;193:1172-1177.
13. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-107.
14. Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001;120:1438-1447.
15. Ji X, Cheung R, Cooper S, Li Q, Greenberg HB, He XS. Interferon alpha regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. HEPATOLOGY 2003;37:610-621.
16. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002;19:1-46.
17. Wang E, Miller LD, Ohnmacht GA, Liu ET, Marincola FM. High-fidelity mRNA amplification for gene profiling. Nat Biotechnol 2000;18:457-459.
18. Eisen MB, Brown PO. DNA arrays for analysis of gene expression. Methods Enzymol 1999;303:179-205.
19. Sherlock G, Hernandez-Boussard T, Kasarskis A, Binkley G, Matese JC, Dwight SS, et al. The Stanford Microarray Database. Nucleic Acids Res 2001;29:152-155.
20. Krutzik PO, Nolan GP. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A 2003;55:61-70.
21. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-5121.
22. Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud O, Gjertsen BT, et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004;118:217-228.
23. Krutzik PO, Hale MB, Nolan GP. Characterization of the murine immunological signaling network with phosphospecific flow cytometry. J Immunol 2005;175:2366-2373.
24. Sen GC. Viruses and interferons. Annu Rev Microbiol 2001;55:255-281.
25. Hu KQ, Vierling JM, Redeker AG. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepat 2001;8:1-18.
26. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alpha-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-1023 [discussion 1947].